Eli Lilly and Company (NYSE:LLY) CAO Sells $2,370,020.00 in Stock

Eli Lilly and Company (NYSE:LLY) CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eli Lilly and Company Trading Down 0.8%

Shares of LLY stock opened at $1,211.13 on Friday. Eli Lilly and Company has a 12 month low of $655.10 and a 12 month high of $1,249.45. The company has a market cap of $1.14 trillion, a PE ratio of 40.64, a price-to-earnings-growth ratio of 1.44 and a beta of 0.51. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business’s 50 day moving average is $1,169.84 and its two-hundred day moving average is $1,051.85.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the previous year, the company earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts predict that Eli Lilly and Company will post 36.33 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 23.22%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s oral GLP-1 drug Foundayo generated $98 million in second-quarter sales following its April launch. Investors are monitoring early uptake as the pill expands Lilly’s obesity-treatment offerings and could broaden access beyond injectable medicines. Foundayo Q2 sales article
• Positive Sentiment: The company’s recent second-quarter performance continues to support the bullish case: revenue rose 47.7% year over year to $22.97 billion, and EPS of $8.38 exceeded the $6.40 consensus estimate. Strong demand for Mounjaro and Zepbound helped Lilly raise its fiscal 2026 EPS guidance to $35.50–$36.50. Lilly Q2 earnings call transcript
• Positive Sentiment: Lilly filed six lawsuits against U.S. sellers allegedly marketing unauthorized versions of experimental obesity drug retatrutide. The action may help protect future product revenue, brand reputation and patient safety ahead of potential regulatory filings. Reuters retatrutide lawsuits article
• Neutral Sentiment: Novo Nordisk’s CEO said the obesity-drug market is unlikely to be winner-take-all, emphasizing differentiated treatments and oral products. The comments reinforce competition for Lilly but also suggest that a rapidly expanding market may support multiple major players. Reuters Novo Nordisk obesity market article
• Negative Sentiment: At roughly 40 times earnings, Lilly’s premium valuation leaves limited room for execution setbacks. Investors may require continued earnings beats, strong Foundayo adoption and successful next-generation drug launches to justify further gains.
• Negative Sentiment: Chief Accounting Officer Donald Zakrowski sold 2,000 shares worth approximately $2.37 million under a pre-arranged Rule 10b5-1 plan. The scheduled nature reduces its significance, but insider selling can still weigh modestly on sentiment. Lilly insider sale article

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Berenberg Bank increased their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Rothschild & Co Redburn upped their price target on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Morgan Stanley reissued an “overweight” rating and issued a $1,419.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 6th. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a research note on Friday, August 7th. Finally, Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,292.18.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently bought and sold shares of LLY. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares during the period. BlackRock Inc. raised its holdings in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after buying an additional 1,046,558 shares in the last quarter. State Street Corp raised its holdings in shares of Eli Lilly and Company by 1.8% in the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after buying an additional 635,358 shares in the last quarter. Morgan Stanley lifted its position in shares of Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after buying an additional 407,166 shares during the period. Finally, Capital World Investors lifted its position in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after buying an additional 61,851 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.